BFM Patrimoine

STENTYS: COMMUNIQUE

BFM Patrimoine

Regulatory News: STENTYS (Paris:STNT): STENTYS (FR0010949404 – STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardi

Regulatory News:

STENTYS (Paris:STNT):

STENTYS (FR0010949404 – STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced notification that the shares and securities now owned by Mr. Jacques Séguin are all bound by lock-up agreement.

Following his stepping down as a Director and his nomination as a Scientific Advisor to the Company, Prof. Jacques Séguin notified STENTYS about his current shareholding. The Company decided to make this information public.

As of 29 April 2013, Prof. Jacques Séguin only owns STENTYS securities that are locked and cannot be sold until 31 December 2015, in accordance with the Shareholder Agreement signed with Fonds Stratégique d'Investissement (FSI) on 22 October 2012.

  • Upcoming financial results

STENTYS expects to publish its revenues for H1 2013 on 25 July 2013.

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS' Self-Apposing® stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

STENTYS is listed on Comp. C of the NYSE Euronext Paris ISIN: FR0010949404 – Ticker: STNT

STENTYS
CFO Stanislas Piot, +33 (0)1 44 53 99 42 stan.p@stentys.com ou Europe: NewCap. Dusan Oresansky / Pierre Laurent, +33 (0)1 44 71 94 93 stentys@newcap.fr ou US: MacDougall Biomedical Communications Charles Liles, 781 235 3060 Christine Labaree, 650 339 7533 stentys@macbiocom.com

Business Wire